Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.
机构:[1]Department of Endocrinology, Peking University People’s Hospital, Beijing, China[2]PegBio Co., Ltd, Suzhou, China[3]Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China[4]Department of Endocrinology, Nanjing First Hospital, Nanjing, China[5]The Third Endocrinology Department, Cangzhou Central Hospital, Cangzhou, China[6]Department of Endocrinology, Beijing Pinggu Hospital, Beijing, China[7]Department of Endocrinology, Tianjin People’s Hospital, Tianjin, China[8]Department of Endocrinology, The Second Hospital of Jilin University, Changchun, China[9]Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China[10]Department of Endocrinology and Diabetes, Chenzhou No 1 People’s Hospital, Chenzhou, China[11]Department of Endocrinology, Zhongda Hospital Southeast University, Nanjing, China[12]Department of Endocrinology, Jinan Central Hospital, Jinan, China[13]Department of Endocrinology, Luoyang Central Hospital, Luoyang, China[14]Department of Endocrinology, Yuncheng Central Hospital, Yuncheng, China[15]Department of Endocrinology, The First Affiliated Hospital of Henan University of Science and Technology, Henan, China[16]Department of Endocrinology, Qingdao Central Hospital, Qingdao, China[17]Department of Endocrinology, Beijing Union Medical College Hospital, Beijing, China[18]Department of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, China[19]Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China[20]Department of Endocrinology, Xuzhou Central Hospital, Xuzhou, China[21]Department of Endocrinology, The First People’s Hospital, Changde, China[22]Department of Endocrinology, Guangzhou Red Cross Hospital, Guangzhou, China[23]Department of Endocrinology, Xiangya Hospital Central South University, Changsha, China[24]Department of Endocrinology, Guangzhou Panyu Central Hospital, Guangzhou, China[25]Department of Endocrinology, Anhui Provincial Hospital, Hefei, China[26]Department of Endocrinology, Shandong Provincial Hospital, Jinan, China[27]Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao, China[28]Department of Endocrinology, West China Hospital Sichuan University, Sichuan, China四川大学华西医院[29]Department of Endocrinology, Beijing Tongren Hospital, CMU, Beijing, China临床科室内分泌科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[30]Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Henan, China[31]Department of Endocrinology, Affiliated Hospital & Clinical Medical College of Chengdu University, Chengdu, China[32]Department of Endocrinology, Suzhou Municipal Hospital, Suzhou, China
The following sentence in the Discussion was inappropriately
changed to a definite statement during editing: ‘Considering
the mechanism of action of PB-119, which is similar to
exenatide QW, PB-119 also showed superior efficacy
compared with available OADs.’
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|1 区医学
小类|1 区内分泌学与代谢
最新[2023]版:
大类|1 区医学
小类|1 区内分泌学与代谢
第一作者:
第一作者机构:[1]Department of Endocrinology, Peking University People’s Hospital, Beijing, China
通讯作者:
推荐引用方式(GB/T 7714):
Ji Linong,Du Ying,Xu Min,et al.Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.[J].Diabetologia.2021,doi:10.1007/s00125-021-05460-0.
APA:
Ji Linong,Du Ying,Xu Min,Zhou Xiangjun,Mo Zhaohui...&Chen Lei.(2021).Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study..Diabetologia,,
MLA:
Ji Linong,et al."Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.".Diabetologia .(2021)